Digital Health & Artificial Intelligence

 

Digital Health and AI, Monday 17 August 2020

last published: 25/Aug/20 17:55

 

Digital Health and AI, Monday 24 August 2020

Ranjit Kumble
Digital Health and AI
08:30

Developing AI capabilities to rapidly screen complex EMR datasets for rare disease clinical insights and patient identification

Ranjit Kumble, Global Data Science Lead, Customer Analytics And Insights, Pfizer
Christopher Rudolf
Digital Health and AI
08:50

AI in rare diseases and personalized medicines - how diagnostic signals identified from electronic health data can help patients receive earlier diagnosis and treatment

Christopher Rudolf, Founder And Chief Executive Officer, volv global
Marius George Linguraru
Digital Health and AI
09:10

PANEL: Hospital and Industry innovation in patient Identification for rare diseases

Marius George Linguraru, Principal Investigator at Children’s National Health System, Professor of Radiology, Pediatrics and Biomedical Engineering, The George Washington University
Younos Abdulsattar, US Vyndaqel Medical Team Lead, Rare Disease, Pfizer
Christopher Rudolf, Founder And Chief Executive Officer, volv global
09:50

BREAK

Ellen Coleman
10:05

Chairperson’s opening remarks

Ellen Coleman, President And Chief Executive Officer, VOZ Advisors
Jeremy Levin
10:10

Keynote Address: Rare diseases in the time of Covid-19

Jeremy Levin, Chairman and Chief Executive Officer, Chairman, BIO, Ovid Therapeutics
Emil Kakkis
10:35

Keynote Address: The future of rare diseases: developing and accessing the next generation of therapies

Emil Kakkis, Chief Executive Officer, Ultragenyx Pharmaceutical
Neena Nizar
10:55

Keynote Panel: Patient involvement in drug development for rare diseases – examining how patients are driving meaningful development and what companies are doing to incorporate patient input throughou

Neena Nizar, President, The Jansens Foundation
Jessica Scott, Head of R&D Patient Engagement Office,, Takeda Pharmaceuticals
Amy Mckee, Vice President, Regulatory, Parexel Consulting, Parexel International
Dara Richardson-Heron, Chief Patient Officer, Pfizer
Yann Le Cam, Chief Executive Officer, EURORDIS
11:45

EXHIBITOR HALL BREAK

Zheng Yang
Digital Health and AI
12:30

Open Source Imaging Consortium against Fibrosing Interstitial Lung Diseases (ILD) - setting up business and legal framework for success

Zheng Yang, Head Of Technology And Data Innovation, Customer Value, Boehringer Ingelheim
Oodaye Shukla
Digital Health and AI
12:50

Examining industry strategies for leveraging patient data and AI to advance rare disease patient identification, R&D, and commercialization

Oodaye Shukla, Chief Data Officer, HVH Precision Analytics, now EVERSANA
Oodaye Shukla
Digital Health and AI
13:10

PANEL: Transforming rare disease drug discovery models through open science and artificial intelligence

Moderator: Oodaye Shukla, Chief Data Officer, HVH Precision Analytics, now EVERSANA
Zheng Yang, Head Of Technology And Data Innovation, Customer Value, Boehringer Ingelheim
Hubert Misztela, Machine Learning Expert At Novartis, Lecturer At Dublin Business School, Novartis
13:50

BREAK

Amanda Finlayson
14:10

ROUNDTABLE 1: Balancing the Patient Experience & ROI – understanding when to incorporate patient accommodations into study programs and balancing short and long term financial goals

Amanda Finlayson, Therapeutic Strategy Lead, ClinEdge
David Lapidus
14:10

ROUNDTABLE 2: Forecasting & epidemiology - rare-disease epidemiology methods and resources to support commercial forecasts

David Lapidus, President, Lapidus Data
Sam Lucas
14:10

ROUNDTABLE 3: Expanded Access Programs- How EAPs can complement rare disease drug development and optimize commercial launch

Sam Lucas, SVP, Expanded Access Programs, Durbin
Julia Campbell, VP, Client Strategies and Services, Durbin
Todd Galles, VP, US Business Development, EAPs, Durbin
Janet Maynard
14:10

ROUNDTABLE 4: FDA updates - Office of Orphan Product Development

Janet Maynard, Director, Office Of Orphan Products Development, Food And Drug Administration, U.S. Food and Drug Administration
Lewis Fermaglich, Medical Advisor, Office of Orphan Products Development,, FDA
15:10

BREAK

Panna Sharma
Digital Health and AI
15:20

Leveraging AI for discovery and repurposing drugs— making data valuable through interdisciplinary collaboration and rethinking business models for rare diseases and cancer in the age of AI

Panna Sharma, President And Chief Executive Officer, Lantern Pharma
Oodaye Shukla
17:00

Keynote Panel: Examining industry strategies for leveraging patient data and AI to advance rare disease patient identification, R&D, and commercialization

Moderator: Oodaye Shukla, Chief Data Officer, HVH Precision Analytics, now EVERSANA
Thomas Abbott, Head, Real World Data And Evidence, Astellas Pharma
Sonalee Agarwal, Vice President Of Value And Evidence Strategy, Alnylam Pharmaceuticals
Sean Khozin, Global Head Of Data Strategy, Johnson & Johnson
last published: 25/Aug/20 17:55